Advil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs
Advil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs By Richa Naidu
LONDON, Sept 16 (Reuters) - Consumer health company Haleon HLN.L has achieved growing sales of products to counter side-effects of weight-loss drugs in the United States, the company said, capitalising on the rising popularity of GLP-1 medication.
Drugs such as Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound and Foundayo help people to lose weight by mimicking a hormone that keeps the stomach feeling full.
Potential side-effects from these GLP-1 drugs include nausea, vomiting, constipation and diarrhea. Some people also experience abdominal pain and stomach cramps.
Haleon, which makes Advil pain relief pills, TUMS indigestion tablets and Biotène oral-care gels, said it is working with U.S.-based stores including CVS Pharmacy CVS.N to put its products in spaces curated for GLP-1 drug users as well as on regular store aisles.
"Dual placement in core aisles and GLP-1 destination sets delivers an average 24% sales lift per store," a Haleon spokesperson said of the previously unreported strategy. The sales increase was recorded in the first quarter of the year.
"Haleon holds the majority of GLP-1 shelf space at CVS," the spokesperson added, noting that curated items on dedicated GLP-1 shelves in stores are outperforming the same items in stores without one.
About 11% of Americans are on GLP-1 weight-loss drugs, according to analytics company Gallup.
"CVS Pharmacy has expanded its product assortment and is highlighting CVS brand and national brand over-the-counter products to help make managing side effects easier," the retailer said in a statement without addressing Haleon's comments directly.
London-listed Haleon has also spoken to retail giants Walmart WMT.O and Target TGT.N about its GLP-1 in-store strategy, the Haleon spokesperson added without disclosing the outcome of those talks.
(Reporting by Richa Naidu
Editing by David Goodman)((richa.naidu@tr.com; Follow me on BlueSky @richanaidu.bsky.social; +44 755 755 9587;))
Recent news on CVS Health
See all newsHealth Rounds: GLP-1 drugs tied to heart improvements in patients with obesity and heart failure
US health insurers fall for third day on CMS audit proposal, Medicare-for-All concerns
Health insurers extend decline on proposed new rule to curb fraud
Health insurers extend decline on proposed new rule to curb fraud
UnitedHealthcare to expand program paying pharmacists for medical services